New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How would you manage aplastic anemia refractory to multiple agents?

1 Answers

Mednet MemberInvited Expert
Hematology · Dana-Farber Cancer Institute

If indeed the patient has been treated with all reasonable alternatives to BMT, the choices are 1) watch and wait with supportive care or 2) bone marrow transplantation. I understand the reluctance of transplanting someone in their 70s with aplastic anemia; however, we do this routinely in patients ...

What is your preferred therapy for MDS/MPN with significant leukocytosis and neutrophilia?

1 Answers

Mednet MemberInvited Expert
Hematology · UMass Chan Medical School

Depends on blast count, cytogenetics, and molecular test results, age of patient, performance status, comorbidities, etc. To bring the white count down can temporarily start with hydroxyurea. would use induction chemo versus HMA +/- venetoclax to achieve at least a partial response. can be a candida...

How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Texas Southwestern Medical Center

BV-AVD-related transaminitis is relatively common; however, even with Nivo-AVD, transaminitis is frequently observed, albeit at a lower frequency. Most of these events are self-limited and grade 1-2. Depending on the stage and severity of the event, dose holds can be employed; however, adverse event...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What is your re-immunization strategy after auto SCT for patients with myeloma on dara/len maintenance?

3 Answers

Mednet MemberInvited Expert
Medical Oncology · OhioHealth

We do the same vaccination sequence according to BMT/CTN, whether they are on maintenance dara or not. Here is our schedule Post autologous SCT vaccine Interval Date Vaccine Yearly Flu Vaccine 3-month post-transplant Pneumovax 20, Hib, hep A/hep B, polio, TDap, Shingrix 6 months post-transplant Pneu...

How would you define your radiation treatment volume for a primary diffuse large B-cell lymphoma of the L4 vertebral body that had a complete response to chemotherapy?

1 Answers

Mednet Member
Radiation Oncology · University of Utah School of Medicine

For a primary DLBCL involving only the L4 vertebral body with a CR after chemotherapy, we would include just the involved L4 vertebral body. There is no need to include one vertebral body above and below. Effort should be made to reduce excess dose to the bowel and adjacent bone marrow with either a...

What is your approach to further work-up and management of neutropenia in patients with SLE/RA overlap?

4
2 Answers

Mednet MemberInvited Expert
Rheumatology · Mobile Medical Care Inc

This is an interesting situation that comes up in the routine evaluation of patients with rheumatoid arthritis and other autoimmune syndromes. The normocellular bone marrow suggests a peripheral destruction, in general, and raises some concerns for antibodies directed against neutrophils. These are ...

How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Riverside Methodist Hospitals/OhioHealth

In my experience, true refractoriness to methotrexate and cyclophosphamide is unusual in LGL. What is more usual is that patients take a long time to respond and I usually don’t change therapy before a full 6 months trial of either agents. That is also what the published data suggests. In the meanwh...

How do you manage a patient with sickle cell disease during pregnancy?

1
2 Answers

Mednet MemberInvited Expert
Hematology · University of Maryland

I refer all pregnant women with SCD to maternofetal medicine/high risk pregnancy clinic for more frequent monitoring. I recommend a baby aspirin for preeclampsia prevention (see UK guidelines). I recommend folic acid 4 mg. If they do have iron overload, I do not recommend iron supplementation. For a...

Do you choose to include or omit growth factor support in the treatment of Hodgkins lymphoma?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Mississippi Medical Center

I typically do not use "up front" growth factor support unless my patient is frail. If symptomatic neutropenia develops during therapy I will add growth factor support at that time. For the patient with asymptomatic neutropenia I will continue therapy and individualize the decision for the addition ...

Does stopping anagrelide affect fibrosis in patients with ET who develop post-ET myelofibrosis?

1 Answers

Mednet MemberInvited Expert
Hematology · Johns Hopkins University

Anagrelide is a phosphodiesterase (PDE) III inhibitor, developed initially as a platelet antiaggregant, but was found to have platelet lowering activity at concentrations lower than its platelet antiaggregant activity. Thus, it was consequently marketed to reduce thrombocytosis in MPN patients. It i...